Starling Oncology, Inc. (NASDAQ: STLN) Stock Competitors & Peer Comparison
See STLN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STLN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STLN | $6.40 | +1.43% | 639.9M | N/A | N/A | N/A |
| HCA | $411.73 | +1.67% | 89.2B | 14.22 | $28.96 | +0.74% |
| THC | $270.21 | +2.14% | 21.8B | 15.68 | $17.24 | N/A |
| FMS | $23.56 | +0.26% | 12.7B | 8.86 | $2.66 | +3.67% |
| EHC | $122.10 | +0.09% | 12.1B | 20.91 | $5.84 | +0.62% |
| BTSGU | $196.51 | -1.01% | 11.5B | 177.28 | $1.11 | N/A |
| DVA | $177.91 | +0.68% | 11.4B | 13.90 | $12.80 | N/A |
| ENSG | $182.49 | +0.53% | 10.6B | 26.45 | $6.90 | +0.14% |
| UHS | $173.09 | +1.50% | 10.5B | 7.68 | $22.54 | +0.47% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
STLN vs HCA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, HCA has a market cap of 89.2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while HCA trades at $411.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HCA's P/E ratio is 14.22. In terms of profitability, STLN's ROE is +2.10%, compared to HCA's ROE of -1.13%. Regarding short-term risk, STLN is more volatile compared to HCA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
STLN vs THC Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, THC has a market cap of 21.8B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while THC trades at $270.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas THC's P/E ratio is 15.68. In terms of profitability, STLN's ROE is +2.10%, compared to THC's ROE of +0.51%. Regarding short-term risk, STLN is more volatile compared to THC. This indicates higher risk in terms of short-term price fluctuations for STLN.Check THC's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
STLN vs FMS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, FMS has a market cap of 12.7B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while FMS trades at $23.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FMS's P/E ratio is 8.86. In terms of profitability, STLN's ROE is +2.10%, compared to FMS's ROE of +0.07%. Regarding short-term risk, STLN is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FMS's competition here
Encompass Health Corporation (NYSE: EHC)
STLN vs EHC Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while EHC trades at $122.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EHC's P/E ratio is 20.91. In terms of profitability, STLN's ROE is +2.10%, compared to EHC's ROE of +0.25%. Regarding short-term risk, STLN is more volatile compared to EHC. This indicates higher risk in terms of short-term price fluctuations for STLN.Check EHC's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
STLN vs BTSGU Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, BTSGU has a market cap of 11.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while BTSGU trades at $196.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is 177.28. In terms of profitability, STLN's ROE is +2.10%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, STLN is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for STLN.Check BTSGU's competition here
DaVita Inc. (NYSE: DVA)
STLN vs DVA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, DVA has a market cap of 11.4B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while DVA trades at $177.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DVA's P/E ratio is 13.90. In terms of profitability, STLN's ROE is +2.10%, compared to DVA's ROE of -1.24%. Regarding short-term risk, STLN is more volatile compared to DVA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check DVA's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
STLN vs ENSG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ENSG has a market cap of 10.6B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ENSG trades at $182.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ENSG's P/E ratio is 26.45. In terms of profitability, STLN's ROE is +2.10%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, STLN is more volatile compared to ENSG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ENSG's competition here
Universal Health Services, Inc. (NYSE: UHS)
STLN vs UHS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, UHS has a market cap of 10.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while UHS trades at $173.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas UHS's P/E ratio is 7.68. In terms of profitability, STLN's ROE is +2.10%, compared to UHS's ROE of +0.21%. Regarding short-term risk, STLN is more volatile compared to UHS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check UHS's competition here
Oak Street Health, Inc. (NYSE: OSH)
STLN vs OSH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas OSH's P/E ratio is -17.65. In terms of profitability, STLN's ROE is +2.10%, compared to OSH's ROE of +4.64%. Regarding short-term risk, STLN is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check OSH's competition here
PACS Group, Inc. (NYSE: PACS)
STLN vs PACS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, PACS has a market cap of 6.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while PACS trades at $43.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PACS's P/E ratio is 23.17. In terms of profitability, STLN's ROE is +2.10%, compared to PACS's ROE of +0.27%. Regarding short-term risk, STLN is more volatile compared to PACS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check PACS's competition here
Chemed Corporation (NYSE: CHE)
STLN vs CHE Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CHE has a market cap of 6.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CHE trades at $529.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CHE's P/E ratio is 24.50. In terms of profitability, STLN's ROE is +2.10%, compared to CHE's ROE of +0.29%. Regarding short-term risk, STLN is more volatile compared to CHE. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CHE's competition here
LHC Group, Inc. (NASDAQ: LHCG)
STLN vs LHCG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas LHCG's P/E ratio is 82.83. In terms of profitability, STLN's ROE is +2.10%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, STLN is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
STLN vs LFST Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, LFST has a market cap of 4.8B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while LFST trades at $12.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas LFST's P/E ratio is 93.09. In terms of profitability, STLN's ROE is +2.10%, compared to LFST's ROE of +0.03%. Regarding short-term risk, STLN is more volatile compared to LFST. This indicates higher risk in terms of short-term price fluctuations for STLN.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
STLN vs CON Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CON has a market cap of 4.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CON trades at $35.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CON's P/E ratio is 24.35. In terms of profitability, STLN's ROE is +2.10%, compared to CON's ROE of +0.47%. Regarding short-term risk, STLN is more volatile compared to CON. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CON's competition here
National HealthCare Corporation (AMEX: NHC)
STLN vs NHC Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NHC has a market cap of 3.7B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NHC trades at $234.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NHC's P/E ratio is 29.77. In terms of profitability, STLN's ROE is +2.10%, compared to NHC's ROE of +0.13%. Regarding short-term risk, STLN is more volatile compared to NHC. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
STLN vs OPCH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, OPCH has a market cap of 3.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while OPCH trades at $23.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas OPCH's P/E ratio is 13.61. In terms of profitability, STLN's ROE is +2.10%, compared to OPCH's ROE of +0.16%. Regarding short-term risk, STLN is more volatile compared to OPCH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check OPCH's competition here
Amedisys, Inc. (NASDAQ: AMED)
STLN vs AMED Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMED's P/E ratio is 39.30. In terms of profitability, STLN's ROE is +2.10%, compared to AMED's ROE of +0.11%. Regarding short-term risk, STLN is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AMED's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
STLN vs BKD Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while BKD trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BKD's P/E ratio is -21.09. In terms of profitability, STLN's ROE is +2.10%, compared to BKD's ROE of +4.06%. Regarding short-term risk, STLN is more volatile compared to BKD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check BKD's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
STLN vs AVAH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AVAH has a market cap of 2.8B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AVAH trades at $12.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AVAH's P/E ratio is 18.63. In terms of profitability, STLN's ROE is +2.10%, compared to AVAH's ROE of +1.50%. Regarding short-term risk, STLN is more volatile compared to AVAH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AVAH's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
STLN vs ACHC Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ACHC has a market cap of 2.6B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ACHC trades at $27.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ACHC's P/E ratio is 13.80. In terms of profitability, STLN's ROE is +2.10%, compared to ACHC's ROE of -0.50%. Regarding short-term risk, STLN is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ACHC's competition here
Guardian Pharmacy Services, Inc. (NYSE: GRDN)
STLN vs GRDN Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while GRDN trades at $38.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GRDN's P/E ratio is 33.56. In terms of profitability, STLN's ROE is +2.10%, compared to GRDN's ROE of +0.31%. Regarding short-term risk, STLN is more volatile compared to GRDN. This indicates higher risk in terms of short-term price fluctuations for STLN.Check GRDN's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
STLN vs ADUS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ADUS has a market cap of 2.2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ADUS trades at $118.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ADUS's P/E ratio is 17.68. In terms of profitability, STLN's ROE is +2.10%, compared to ADUS's ROE of +0.10%. Regarding short-term risk, STLN is more volatile compared to ADUS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ADUS's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
STLN vs MD Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while MD trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MD's P/E ratio is 11.86. In terms of profitability, STLN's ROE is +2.10%, compared to MD's ROE of +0.20%. Regarding short-term risk, STLN is more volatile compared to MD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MD's competition here
Select Medical Holdings Corporation (NYSE: SEM)
STLN vs SEM Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SEM has a market cap of 2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SEM's P/E ratio is 15.43. In terms of profitability, STLN's ROE is +2.10%, compared to SEM's ROE of +0.08%. Regarding short-term risk, STLN is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
STLN vs ASTH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ASTH trades at $39.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ASTH's P/E ratio is 37.65. In terms of profitability, STLN's ROE is +2.10%, compared to ASTH's ROE of +0.05%. Regarding short-term risk, STLN is more volatile compared to ASTH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ASTH's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
STLN vs SNDA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SNDA has a market cap of 1.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SNDA trades at $40.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SNDA's P/E ratio is -7.49. In terms of profitability, STLN's ROE is +2.10%, compared to SNDA's ROE of -0.26%. Regarding short-term risk, STLN is more volatile compared to SNDA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SNDA's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
STLN vs SGRY Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SGRY has a market cap of 1.9B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SGRY trades at $14.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SGRY's P/E ratio is 36.51. In terms of profitability, STLN's ROE is +2.10%, compared to SGRY's ROE of -0.05%. Regarding short-term risk, STLN is more volatile compared to SGRY. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SGRY's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
STLN vs AMEH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMEH's P/E ratio is 39.25. In terms of profitability, STLN's ROE is +2.10%, compared to AMEH's ROE of +0.05%. Regarding short-term risk, STLN is more volatile compared to AMEH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AMEH's competition here
Agilon Health, Inc. (NYSE: AGL)
STLN vs AGL Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AGL trades at $95.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AGL's P/E ratio is -10.68. In terms of profitability, STLN's ROE is +2.10%, compared to AGL's ROE of -1.19%. Regarding short-term risk, STLN is more volatile compared to AGL. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AGL's competition here
Ardent Health Inc. (NYSE: ARDT)
STLN vs ARDT Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ARDT has a market cap of 1.6B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ARDT trades at $10.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ARDT's P/E ratio is 8.83. In terms of profitability, STLN's ROE is +2.10%, compared to ARDT's ROE of +0.05%. Regarding short-term risk, STLN is more volatile compared to ARDT. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ARDT's competition here
Innovage Holding Corp. (NASDAQ: INNV)
STLN vs INNV Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while INNV trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas INNV's P/E ratio is -123.33. In terms of profitability, STLN's ROE is +2.10%, compared to INNV's ROE of -0.09%. Regarding short-term risk, STLN is more volatile compared to INNV. This indicates higher risk in terms of short-term price fluctuations for STLN.Check INNV's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
STLN vs HCSG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while HCSG trades at $21.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HCSG's P/E ratio is 17.55. In terms of profitability, STLN's ROE is +2.10%, compared to HCSG's ROE of +0.24%. Regarding short-term risk, STLN is more volatile compared to HCSG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check HCSG's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
STLN vs PNTG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while PNTG trades at $39.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PNTG's P/E ratio is 29.85. In terms of profitability, STLN's ROE is +2.10%, compared to PNTG's ROE of +0.10%. Regarding short-term risk, STLN is more volatile compared to PNTG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check PNTG's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
STLN vs AMN Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AMN trades at $34.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMN's P/E ratio is 11.48. In terms of profitability, STLN's ROE is +2.10%, compared to AMN's ROE of +0.15%. Regarding short-term risk, STLN is more volatile compared to AMN. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AMN's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
STLN vs NUTX Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NUTX has a market cap of 1.3B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NUTX trades at $187.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 14.50. In terms of profitability, STLN's ROE is +2.10%, compared to NUTX's ROE of +0.52%. Regarding short-term risk, STLN is more volatile compared to NUTX. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NUTX's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
STLN vs BKDT Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BKDT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to BKDT's ROE of +4.06%. Regarding short-term risk, STLN is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for STLN.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
STLN vs USPH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while USPH trades at $78.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas USPH's P/E ratio is 30.80. In terms of profitability, STLN's ROE is +2.10%, compared to USPH's ROE of -0.01%. Regarding short-term risk, STLN is more volatile compared to USPH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check USPH's competition here
Talkspace, Inc. (NASDAQ: TALK)
STLN vs TALK Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TALK trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TALK's P/E ratio is 774.34. In terms of profitability, STLN's ROE is +2.10%, compared to TALK's ROE of +0.00%. Regarding short-term risk, STLN is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TALK's competition here
Fidelity Select Health Care Svcs Port (NASDAQ: FSHCX)
STLN vs FSHCX Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, FSHCX has a market cap of 872.8M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while FSHCX trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FSHCX's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to FSHCX's ROE of N/A. Regarding short-term risk, STLN is more volatile compared to FSHCX. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FSHCX's competition here
GMR Solutions Inc. (NYSE: GMRS)
STLN vs GMRS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, GMRS has a market cap of 763.7M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while GMRS trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GMRS's P/E ratio is 6.28. In terms of profitability, STLN's ROE is +2.10%, compared to GMRS's ROE of +0.16%. Regarding short-term risk, STLN is more volatile compared to GMRS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check GMRS's competition here
Enhabit, Inc. (NYSE: EHAB)
STLN vs EHAB Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EHAB's P/E ratio is -197.14. In terms of profitability, STLN's ROE is +2.10%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, STLN is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for STLN.Check EHAB's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
STLN vs TOI Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TOI trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TOI's P/E ratio is -14.25. In terms of profitability, STLN's ROE is +2.10%, compared to TOI's ROE of +2.10%. Regarding short-term risk, STLN is more volatile compared to TOI. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TOI's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
STLN vs SRTA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SRTA has a market cap of 493.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SRTA trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SRTA's P/E ratio is -26.87. In terms of profitability, STLN's ROE is +2.10%, compared to SRTA's ROE of +0.14%. Regarding short-term risk, STLN is more volatile compared to SRTA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SRTA's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
STLN vs MCTA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MCTA's P/E ratio is 419.36. In terms of profitability, STLN's ROE is +2.10%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, STLN is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MCTA's competition here
Community Health Systems, Inc. (NYSE: CYH)
STLN vs CYH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CYH has a market cap of 421.6M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CYH trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CYH's P/E ratio is 4.10. In terms of profitability, STLN's ROE is +2.10%, compared to CYH's ROE of +0.21%. Regarding short-term risk, STLN is more volatile compared to CYH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
STLN vs AUNA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AUNA has a market cap of 402M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AUNA trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AUNA's P/E ratio is 4.89. In terms of profitability, STLN's ROE is +2.10%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, STLN is more volatile compared to AUNA. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AUNA's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
STLN vs VMD Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, VMD has a market cap of 347.4M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while VMD trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 25.33. In terms of profitability, STLN's ROE is +2.10%, compared to VMD's ROE of +0.10%. Regarding short-term risk, STLN is more volatile compared to VMD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check VMD's competition here
Capital Senior Living Corporation (NYSE: CSU)
STLN vs CSU Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CSU's P/E ratio is 0.67. In terms of profitability, STLN's ROE is +2.10%, compared to CSU's ROE of -0.33%. Regarding short-term risk, STLN is more volatile compared to CSU. This indicates higher risk in terms of short-term price fluctuations for STLN.Check CSU's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
STLN vs AIRS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AIRS has a market cap of 190.1M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AIRS trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIRS's P/E ratio is -89.83. In terms of profitability, STLN's ROE is +2.10%, compared to AIRS's ROE of -0.13%. Regarding short-term risk, STLN is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIRS's competition here
The Joint Corp. (NASDAQ: JYNT)
STLN vs JYNT Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, JYNT has a market cap of 121.7M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while JYNT trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas JYNT's P/E ratio is 85.40. In terms of profitability, STLN's ROE is +2.10%, compared to JYNT's ROE of +0.22%. Regarding short-term risk, STLN is more volatile compared to JYNT. This indicates higher risk in terms of short-term price fluctuations for STLN.Check JYNT's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
STLN vs PARK Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, PARK has a market cap of 99.1M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while PARK trades at $21.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PARK's P/E ratio is 29.65. In terms of profitability, STLN's ROE is +2.10%, compared to PARK's ROE of -0.00%. Regarding short-term risk, STLN is more volatile compared to PARK. This indicates higher risk in terms of short-term price fluctuations for STLN.Check PARK's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
STLN vs FVE Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FVE's P/E ratio is -5.64. In terms of profitability, STLN's ROE is +2.10%, compared to FVE's ROE of -0.15%. Regarding short-term risk, STLN is more volatile compared to FVE. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
STLN vs KDLYW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas KDLYW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, STLN is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check KDLYW's competition here
biote Corp. (NASDAQ: BTMD)
STLN vs BTMD Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, BTMD has a market cap of 57.3M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while BTMD trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BTMD's P/E ratio is 11.82. In terms of profitability, STLN's ROE is +2.10%, compared to BTMD's ROE of -0.09%. Regarding short-term risk, STLN is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for STLN.Check BTMD's competition here
DocGo Inc. (NASDAQ: DCGO)
STLN vs DCGO Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, DCGO has a market cap of 46.9M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while DCGO trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DCGO's P/E ratio is -0.25. In terms of profitability, STLN's ROE is +2.10%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, STLN is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for STLN.Check DCGO's competition here
AlerisLife Inc. (NASDAQ: ALR)
STLN vs ALR Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ALR's P/E ratio is -1.11. In terms of profitability, STLN's ROE is +2.10%, compared to ALR's ROE of -0.15%. Regarding short-term risk, STLN is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check ALR's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
STLN vs PIII Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, PIII has a market cap of 35.3M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while PIII trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas PIII's P/E ratio is -0.27. In terms of profitability, STLN's ROE is +2.10%, compared to PIII's ROE of +1.61%. Regarding short-term risk, STLN is more volatile compared to PIII. This indicates higher risk in terms of short-term price fluctuations for STLN.Check PIII's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
STLN vs IMAC Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas IMAC's P/E ratio is -2.27. In terms of profitability, STLN's ROE is +2.10%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, STLN is more volatile compared to IMAC. This indicates higher risk in terms of short-term price fluctuations for STLN.Check IMAC's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
STLN vs CCEL Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CCEL has a market cap of 31M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CCEL trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CCEL's P/E ratio is -12.80. In terms of profitability, STLN's ROE is +2.10%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, STLN is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CCEL's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
STLN vs EUDA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, EUDA has a market cap of 26M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while EUDA trades at $13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -26.23. In terms of profitability, STLN's ROE is +2.10%, compared to EUDA's ROE of +1.20%. Regarding short-term risk, STLN is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check EUDA's competition here
Cano Health, Inc. (NYSE: CANO-WT)
STLN vs CANO-WT Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, STLN is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
STLN vs AIH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIH's P/E ratio is -2.78. In terms of profitability, STLN's ROE is +2.10%, compared to AIH's ROE of +1.16%. Regarding short-term risk, STLN is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIH's competition here
Cano Health, Inc. (NYSE: CANO)
STLN vs CANO Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CANO's P/E ratio is -0.01. In terms of profitability, STLN's ROE is +2.10%, compared to CANO's ROE of -1.49%. Regarding short-term risk, STLN is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
STLN vs FPCG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FPCG's P/E ratio is 0.09. In terms of profitability, STLN's ROE is +2.10%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, STLN is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FPCG's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
STLN vs FTRP Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas FTRP's P/E ratio is -1.22. In terms of profitability, STLN's ROE is +2.10%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, STLN is more volatile compared to FTRP. This indicates higher risk in terms of short-term price fluctuations for STLN.Check FTRP's competition here
American Shared Hospital Services (AMEX: AMS)
STLN vs AMS Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AMS has a market cap of 9.8M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AMS trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AMS's P/E ratio is -6.65. In terms of profitability, STLN's ROE is +2.10%, compared to AMS's ROE of -0.07%. Regarding short-term risk, STLN is more volatile compared to AMS. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AMS's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
STLN vs BMGL Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, BMGL has a market cap of 8.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while BMGL trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas BMGL's P/E ratio is -0.99. In terms of profitability, STLN's ROE is +2.10%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, STLN is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for STLN.Check BMGL's competition here
XWELL, Inc. (NASDAQ: XWEL)
STLN vs XWEL Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, XWEL has a market cap of 7.3M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while XWEL trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas XWEL's P/E ratio is -0.17. In terms of profitability, STLN's ROE is +2.10%, compared to XWEL's ROE of +3.18%. Regarding short-term risk, STLN is more volatile compared to XWEL. This indicates higher risk in terms of short-term price fluctuations for STLN.Check XWEL's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
STLN vs AIDX Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AIDX has a market cap of 6.3M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AIDX trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AIDX's P/E ratio is -0.97. In terms of profitability, STLN's ROE is +2.10%, compared to AIDX's ROE of +1.92%. Regarding short-term risk, STLN is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for STLN.Check AIDX's competition here
ModivCare Inc. (NASDAQ: MODV)
STLN vs MODV Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MODV's P/E ratio is -0.06. In terms of profitability, STLN's ROE is +2.10%, compared to MODV's ROE of +1.36%. Regarding short-term risk, STLN is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MODV's competition here
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst (NASDAQ: STLNW)
STLN vs STLNW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, STLNW has a market cap of 5.6M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while STLNW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas STLNW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to STLNW's ROE of N/A. Regarding short-term risk, STLN is more volatile compared to STLNW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check STLNW's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
STLN vs GBNH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas GBNH's P/E ratio is -0.06. In terms of profitability, STLN's ROE is +2.10%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, STLN is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for STLN.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
STLN vs RHE-PA Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, STLN's ROE is +2.10%, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, STLN is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for STLN.Check RHE-PA's competition here
Regional Health Properties, Inc. (AMEX: RHE)
STLN vs RHE Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas RHE's P/E ratio is -1.79. In terms of profitability, STLN's ROE is +2.10%, compared to RHE's ROE of -1.31%. Regarding short-term risk, STLN is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for STLN.Check RHE's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
STLN vs TOIIW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, STLN's ROE is +2.10%, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, STLN is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TOIIW's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
STLN vs IMACW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas IMACW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, STLN is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check IMACW's competition here
Nakamoto Inc. (NASDAQ: NAKAW)
STLN vs NAKAW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NAKAW has a market cap of 1.5M. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NAKAW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NAKAW's P/E ratio is -0.53. In terms of profitability, STLN's ROE is +2.10%, compared to NAKAW's ROE of -1.05%. Regarding short-term risk, STLN is more volatile compared to NAKAW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NAKAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
STLN vs CCM Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, CCM has a market cap of 665.5K. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while CCM trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas CCM's P/E ratio is -0.31. In terms of profitability, STLN's ROE is +2.10%, compared to CCM's ROE of +0.06%. Regarding short-term risk, STLN is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for STLN.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
STLN vs NIVF Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NIVF has a market cap of 104.1K. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NIVF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NIVF's P/E ratio is 0.27. In terms of profitability, STLN's ROE is +2.10%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, STLN is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for STLN.Check NIVF's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
STLN vs MNDR Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, MNDR has a market cap of 42.1K. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while MNDR trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas MNDR's P/E ratio is -0.04. In terms of profitability, STLN's ROE is +2.10%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, STLN is more volatile compared to MNDR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check MNDR's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
STLN vs NIVFW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NIVFW has a market cap of 39.8K. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, STLN's ROE is +2.10%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, STLN is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NIVFW's competition here
Talkspace, Inc. (NASDAQ: TALKW)
STLN vs TALKW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TALKW's P/E ratio is 0.00. In terms of profitability, STLN's ROE is +2.10%, compared to TALKW's ROE of +0.00%. Regarding short-term risk, STLN is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check TALKW's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
STLN vs TVTY Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TVTY's P/E ratio is 19.06. In terms of profitability, STLN's ROE is +2.10%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, STLN is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TVTY's competition here
Kindred Healthcare, Inc. (NYSE: KND)
STLN vs KND Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, KND has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas KND's P/E ratio is -1.14. In terms of profitability, STLN's ROE is +2.10%, compared to KND's ROE of -0.53%. Regarding short-term risk, STLN is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for STLN.Check KND's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
STLN vs ATIP-WT Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, STLN is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for STLN.Check ATIP-WT's competition here
Hanger, Inc. (NYSE: HNGR)
STLN vs HNGR Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas HNGR's P/E ratio is 19.71. In terms of profitability, STLN's ROE is +2.10%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, STLN is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check HNGR's competition here
New Frontier Health Corporation (NYSE: NFH)
STLN vs NFH Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, NFH has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas NFH's P/E ratio is -19.75. In terms of profitability, STLN's ROE is +2.10%, compared to NFH's ROE of -0.06%. Regarding short-term risk, STLN is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for STLN.Check NFH's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
STLN vs SLHGP Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, STLN's ROE is +2.10%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, STLN is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for STLN.Check SLHGP's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
STLN vs SLHG Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas SLHG's P/E ratio is -1.48. In terms of profitability, STLN's ROE is +2.10%, compared to SLHG's ROE of N/A. Regarding short-term risk, STLN is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for STLN.Check SLHG's competition here
Almost Family Inc. (NASDAQ: AFAM)
STLN vs AFAM Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas AFAM's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, STLN is more volatile compared to AFAM. This indicates higher risk in terms of short-term price fluctuations for STLN.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
STLN vs TLMDW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TLMDW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, STLN is more volatile compared to TLMDW. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TLMDW's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
STLN vs TLMD Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas TLMD's P/E ratio is -1.60. In terms of profitability, STLN's ROE is +2.10%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, STLN is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for STLN.Check TLMD's competition here
DocGo Inc. (NASDAQ: DCGOW)
STLN vs DCGOW Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DCGOW's P/E ratio is N/A. In terms of profitability, STLN's ROE is +2.10%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, STLN is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for STLN.Check DCGOW's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
STLN vs DVCR Comparison August 2026
Starling Oncology, Inc. (NASDAQ: STLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STLN stands at 639.9M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, STLN is priced at $6.40 on the NASDAQ, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STLN currently has a P/E ratio of N/A, whereas DVCR's P/E ratio is 28.34. In terms of profitability, STLN's ROE is +2.10%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, STLN is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for STLN.Check DVCR's competition here